Care in a stroke unit improves long-term outcomes for stroke patients, underpinning the enhanced organisation of stroke services now underway across Australia.1,2 An important component of organised acute stroke care is thrombolytic therapy with intravenous tissue plasminogen activator (tPA),2,3 which was licensed for use in Australia in 2003. This highly cost-effective therapy4-6 substantially reduces major disability when used in an expert setting.7,8
Only a small proportion of stroke patients currently receive thrombolytic therapy.9-11 A major factor limiting patient access is that few arrive at expert stroke centres within the narrow 3-hour treatment window. Patient access to tPA could potentially be improved by extending organised stroke care through a cooperative system that crosses the traditional clinical and administrative boundaries of the acute stroke unit, emergency department (ED) and pre-hospital sector.
Where extended organised acute care has been successfully implemented, up to 20% of patients with ischaemic stroke are treated with tPA.12-14 Collaboration with ambulance services is recognised as a key to decreasing the time to presentation for patients with acute stroke. Pre-hospital stroke screening tools, such as the Los Angeles Prehospital Stroke Screen (LAPSS)15 and the Face Arm Speech Test (FAST),16 aid this process. These tools have acceptable diagnostic accuracy in the field and are important components of protocols for pre-hospital stroke care.
John Hunter Hospital, Newcastle, is the principal tertiary referral hospital for the NSW Hunter Region, serving a population of about one million people. The hospital’s acute stroke team comprises an on-call stroke neurologist and an acute stroke nurse, as well as ED medical and nursing staff, and radiology staff.
lack of awareness among ambulance officers of the evidence and requirements for rapid access to organised acute stroke care;
delivery of potentially thrombolysis-eligible patients to hospitals within the Hunter Region not equipped to provide a stroke thrombolysis service; and
delays in acute stroke team notification on arrival of potentially thrombolysis-eligible stroke patients in the ED.
To resolve these problems, the steering committee developed firstly a pre-hospital stroke assessment tool for ambulance officers, and secondly a pre-hospital notification system.
The pre-hospital stroke assessment tool was adapted from the United Kingdom FAST tool,16 to complement the National Stroke Foundation FAST community awareness campaign and existing assessment tools used by NSW ambulance officers. The local GAS-T tool has four elements:
G = glucose in the “normal” range (4–17 mmol/L);
A = arm drift, grip strength;
S = speech disturbance; and
An important difference from the UK tool is the replacement of the more difficult facial asymmetry test, “F”, with a simple finger-prick glucose test, “G”. Hyperglycaemia is a relative contraindication to tPA, being associated with poor outcomes and higher rates of haemorrhagic transformation,17 while hypoglycaemia is a known stroke mimic and may have led to reduced diagnostic accuracy in the field. “T” was added to the tool to emphasise the importance of the 2-hour time window. Although tPA is licensed for treatment of patients with ischaemic stroke within 3 hours of symptom onset, the third hour was allocated to in-hospital pretreatment procedures, such as patient assessment, imaging and gaining patient assent.
The study was a prospective cohort study using historical controls from the same hospital in the corresponding period 1 year earlier. The study population comprised all patients with an initial diagnosis of acute stroke presenting to John Hunter Hospital. The intervention (PAST) group were those patients who presented to the hospital in the 6-month period from September 2006 to March 2007, immediately after implementation of the PAST protocol. The control group were those patients who presented in the corresponding period a year earlier, September 2005 to March 2006. Apart from the PAST protocol, the operating policies and procedures used by the acute stroke team were standard and did not alter over the period of the PAST protocol evaluation.
The primary outcome measure was the proportion of ischaemic stroke patients who received intravenous tPA therapy in the PAST versus the control group.
Tertiary outcome measures were based on clinical outcome at 3 months measured by the modified Rankin score (a validated disability measure where 0–1 = excellent outcome; 2 = functional independence; 3 =moderate disability; and 4–5 = major disability).18,19 Outcomes were compared between patients treated with tPA in the PAST group, and patients in the NINDS (National Institute of Neurological Disorders and Stroke) tPA trial7 and the SITS (Safe Implementation of Thrombolysis in Stroke) tPA registry.20
Statistical analyses were performed using Stata version 9 (Stata Corp, College Station, Tex, USA). Continuous data were analysed using the Student t test when the assumption of normality appeared appropriate, and the Wilcoxon rank sum test when we believed this assumption was invalid. Categorical data were analysed using χ2 tests or the Fisher exact test when the expected count in table cells was too low. P values less than 0.05 were considered statistically significant.
During the 6-month PAST protocol period, 232 patients presented to the John Hunter Hospital ED with an initial diagnosis of stroke, and 140 of these (60%) had a final discharge diagnosis of ischaemic stroke (Box 2). Of the 232 patients, 122 (53%) had a defined onset time within the previous 24 hours, and 51 of the 232 were delivered to John Hunter Hospital using the PAST protocol.
In the 6-month control period, 205 patients presented to the John Hunter Hospital ED with an initial diagnosis of stroke, and 107 (52%) had a final discharge diagnosis of ischaemic stroke (Box 2). Of the 205 patients, 61 (30%) had a defined onset time within the previous 24 hours.
There was a statistically significant increase in the proportion of ischaemic stroke patients who received intravenous tPA therapy in the PAST group compared with the control group: 21.4% (95% CI, 14.6%–28.2%) versus 4.7% (95% CI, 1.5%–10.6%); P < 0.001) (Box 3). Expressed as a percentage of all patients presenting to the ED with an initial diagnosis of stroke, 12.9% (95% CI, 8.6%–17.2%) received tPA during the PAST period compared with 2.4% (95% CI, 0.8%–5.6%) during the control period (P < 0.001).
Process of care measures are shown in Box 4. The median time from symptom onset to hospital arrival was reduced by 1 hour in the PAST group compared with the control group (90.5 v 150 min; P = 0.004). The median ED transit time was also reduced in the PAST group (232.5 v 361 minutes in the control group; P < 0.001). Door to needle times among those who received tPA were similar in the two groups (91.5 v 89 minutes; P = 0.40), but very few patients in the control group (five) received tPA.
Three-month outcomes for patients treated with tPA during the PAST period compared favourably with those for tPA-treated patients in the benchmark NINDS tPA trial,7 the SITS international phase IV tPA registry,20 and published Australian audits of tPA implementation8,21 (Box 5). Baseline stroke severity measured by the National Institutes of Health Stroke Scale (NIHSS)7 was worse in our cohort than comparators. Despite this, 43% of our tPA group had minimal or no disability at 3 months, which is at least equivalent to national and international benchmarks.19,22
Audits of tPA use in Australia currently indicate that only 0.9% of all ischaemic stroke patients receive this treatment.9 Given the international evidence that changes in the process of care can substantially increase tPA use,2,23,24 and given the cost effectiveness of tPA therapy,4 there is a clear need to develop support systems and care models to help stroke clinicians in Australia redesign pre-hospital and emergency care systems for acute stroke. Published pre-hospital stroke care protocols have tended to focus on single components of the process of care, such as assessment,25 ED triage,26,27 or in-hospital fast-track protocols.28 PAST is the first Australian stroke protocol that covers both pre-hospital assessment and ED care.
We found that the PAST protocol reduced pre-hospital and ED delays to treatment and significantly increased the proportion of patients treated with intravenous tPA. This partly reflects the substantial reduction in time from symptom onset to hospital arrival during the implementation period. The proportion of patients who arrived at our centre within 2 hours of symptom onset was similar to the proportion who arrived within 3 hours of symptom onset at another Australian centre that had no pre-hospital stroke ambulance protocol in place.23 An additional major benefit of the PAST protocol was the substantial reduction in ED transit time, probably reflecting earlier mobilisation of the stroke team, allowing advance discussions with hospital bed managers.
Our study had potential limitations, particularly the use of historical controls (albeit prospectively collected) and the non-randomised design. This may have resulted in a higher proportion of more severe strokes in the PAST group (Box 2), which may have contributed to the higher rate of early presentation in the PAST period, as these particular strokes may be more readily diagnosed by ambulance officers in the field. Additionally, the retrieval of patients from outside the usual hospital catchment area may have increased the proportion of patients receiving thrombolysis. However, this was a specific aim of the PAST protocol. Indeed, as in most Australian regional areas, these patients would not have had access to thrombolytic therapy before implementation of PAST. While the PAST protocol worked well in the Hunter Region, its geography and systems differ from those in larger metropolitan areas of Australia, where implementation of a similar protocol may be more challenging.
Most importantly, the substantial increase in the proportion of patients treated with tPA during the PAST period is likely to have an impact on stroke-related disability in our region. Using a number needed to treat (NNT) of eight to prevent one case of major disability,7 and with an absolute increase of 25 patients treated during the PAST period, we estimate that over the 6-month period, the protocol prevented three patients from requiring nursing home care. Not only is this meaningful at an individual patient level, but the impact of the protocol being implemented throughout all Australian metropolitan and large regional areas could be substantial. For example, assuming implementation of PAST resulted in a modest increase of 5% in patients treated with thrombolysis Australia-wide (compared with the 16% increase seen in our study), then about 2500 more patients would be treated per annum. Using the same NNT, 312 patients would be saved from major disability, with a cost saving of $31.2 million (from reduced need for rehabilitation and nursing home care) in the first 12 months.4
The prioritisation and preferential transport by ambulance services of patients with suspected stroke to centres with stroke units conforms with the recommendations of the National Strategic Improvement Framework for Heart, Stroke and Vascular Disease28 and the 2007 National Stroke Foundation guidelines.2 While a significant commitment on the part of health care providers would be needed, implementation of “fast-track” protocols such as PAST, supported by well organised, hospital-based stroke care nationwide, would have a substantial impact on stroke-related disability, as well as the resultant burdens and costs to the individual and community. Relatively few therapies have an absolute cost saving. When highly effective therapies are available for a disease of such enormous community impact as stroke, directing efforts and resources towards redesign of pre-hospital and acute stroke care systems appears both desirable and justified.
2 Patient characteristics, by treatment group
Onset within previous 24 h (% of patients with data available) |
|||||||||||||||
Presentation within 2 h of onset (% of patients with data available) |
|||||||||||||||
3 Number of patients with ischaemic stroke and number who received tPA, by treatment group
tPA = tissue plasminogen activator. PAST = Pre-hospital Acute Stroke Triage. |
|||||||||||||||
4 Process measures for patients with a defined symptom onset time within 24 hours of presentation to hospital and for patients who received tPA (values are median and IQR)
5 Distribution of patient outcomes at 3 months after stroke, based on modified Rankin scores, in our study (PAST protocol) and other Australian and international studies
 | |||||||||||||||
|
NINDS = National Institute of Neurological Disorders and Stroke tPA trial.7 SITS = Safe Implementation of Thrombolysis in Stroke tPA registry.20 * Values above columns are the median baseline NIHSS (National Institutes of Health Stroke Scale) scores for each cohort. | |||||||||||||||
Received 9 January 2008, accepted 19 June 2008
Abstract
Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in reducing pre-hospital and emergency department (ED) delays to patients receiving organised acute stroke care, thereby increasing access to thrombolytic therapy.
Design: Prospective cohort study using historical controls.
Setting: Hunter Region of New South Wales, September 2005 to March 2006 (pre-intervention) and September 2006 to March 2007 (post-intervention).
Participants: Consecutive patients presenting with acute stroke to a regional, tertiary referral hospital.
Intervention: PAST protocol, comprising a pre-hospital stroke assessment tool for ambulance officers, an ambulance protocol for hospital bypass for potentially thrombolysis-eligible patients, and pre-hospital notification of the acute stroke team.
Main outcome measures: Proportion of patients who received intravenous tissue plasminogen activator (tPA), process of care time points (symptom onset to ED arrival, ED arrival to tPA treatment, and ED transit time), and clinical outcomes of patients treated with tPA.
Results: The proportion of ischaemic stroke patients treated with tPA increased from 4.7% (pre-intervention) to 21.4% (post-intervention) (P < 0.001). Time point outcomes also improved, with a reduction in median times from symptom onset to ED arrival from 150 to 90.5 min (P = 0.004) and from ED arrival to stroke unit admission from 361 to 232.5 minutes (P < 0.001). Of those treated with tPA, 43% had minimal or no disability at 3 months.
Conclusions: Organised pre-hospital and ED acute stroke care increases patient access to tPA treatment, which is proven to reduce stroke-related disability.